Cargando…

Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: results of an extended multicentre phase-I trial

The aim of this study was to determine the dose-limiting toxicity (DLT) and establish the recommended dose for mitomycin C added every 3 weeks to the standard combination dose of capecitabine. Cohorts of at least three patients with pretreated gastrointestinal carcinoma received capecitabine 1000 mg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hofheinz, R-D, Hartmann, J T, Willer, A, Oechsle, K, Hartung, G, Gnad, U, Saussele, S, Kreil, S, Bokemeyer, C, Hehlmann, R, Hochhaus, A
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2004
Materias:	Clinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409860/ https://www.ncbi.nlm.nih.gov/pubmed/15238990 http://dx.doi.org/10.1038/sj.bjc.6602025

Ejemplares similares

Pegylated liposomal doxorubicin in combination with mitomycin C, infusional 5-fluorouracil and sodium folinic acid. A phase-I-study in patients with upper gastrointestinal cancer
por: Hofheinz, R-D, et al.
Publicado: (2004)

Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial
por: Ernst, T, et al.
Publicado: (2007)

Protracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study
por: Hartmann, J T, et al.
Publicado: (2003)

Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial
por: Nehls, O, et al.
Publicado: (2008)

Survival with chronic myeloid leukaemia after failing milestones
por: Lauseker, Michael, et al.
Publicado: (2023)

A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer
por: Willeke, F, et al.
Publicado: (2007)

Capecitabine-associated hand–foot–skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer
por: Hofheinz, R-D, et al.
Publicado: (2012)

Impact of emerging ACA on survival in chronic myeloid leukemia (CML)
por: Hehlmann, Rüdiger, et al.
Publicado: (2022)

Capecitabine/Mitomycin versus 5-Fluorouracil/Mitomycin in Combination with Simultaneous Integrated Boost Intensity-Modulated Radiation Therapy for Anal Cancer
por: Mineur, Laurent, et al.
Publicado: (2023)

Capecitabine and mitomycin C in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
por: Alliot, C
Publicado: (2006)

Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205
por: Hoehler, T, et al.
Publicado: (2013)

Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer
por: Rao, S, et al.
Publicado: (2004)

Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer
por: Harder, J, et al.
Publicado: (2012)

Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
por: Chong, G, et al.
Publicado: (2005)

Reply: Capecitabine and mitomycin C in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
por: Chong, G, et al.
Publicado: (2006)

Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma
por: Thind, Govin, et al.
Publicado: (2014)

A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei
por: Farquharson, A L, et al.
Publicado: (2008)

Targeting cancers in the gastrointestinal tract: role of capecitabine
por: Saif, Muhammad Wasif
Publicado: (2009)

Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer
por: Price, T J, et al.
Publicado: (2015)

Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer
por: Miger, Jasmine, et al.
Publicado: (2014)

Perceived Positive and Negative Life Changes in Testicular Cancer Survivors
por: Vehling, Sigrun, et al.
Publicado: (2021)

The concept of treatment-free remission in chronic myeloid leukemia
por: Saußele, S, et al.
Publicado: (2016)

Combination Chemotherapy of Mitomycin C and Methotrexate Was Effective on Metastatic Breast Cancer Resistant to Eribulin, Vinorelbine, and Bevacizumab after Anthracycline, Taxane, and Capecitabine
por: Tanabe, Masahiko
Publicado: (2016)

Combination chemotherapy in advanced gastrointestinal cancers: ex vivo sensitivity to gemcitabine and mitomycin C
por: Whitehouse, P A, et al.
Publicado: (2003)

Racial and ethnic differences in capecitabine toxicity in patients with gastrointestinal tract cancers
por: Brazelton, Alicia, et al.
Publicado: (2022)

Brca2 deficiency drives gastrointestinal tumor formation and is selectively inhibited by mitomycin C
por: Chen, Xiaomin, et al.
Publicado: (2020)

Combination chemotherapy with mitomycin C and methotrexate is active against metastatic HER2-negative breast cancer even after treatment with anthracycline, taxane, capecitabine, and vinorelbine
por: Fukuda, Takayo, et al.
Publicado: (2015)

VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer
por: Chionh, Fiona, et al.
Publicado: (2022)

Prof. Michele Baccarani. August 16, 1942 to December 20, 2021: a gifted life in haematology
por: Saglio, Giuseppe, et al.
Publicado: (2022)

Effect of photodynamic therapy in combination with mitomycin C on a mitomycin-resistant bladder cancer cell line.
por: Datta, S. N., et al.
Publicado: (1997)

Phase I study of imatinib, cisplatin and 5-fluoruracil or capecitabine in advanced esophageal and gastric adenocarcinoma
por: Mayr, Martina, et al.
Publicado: (2012)

Treatment-induced anaemia and its potential clinical impact in patients receiving sequential high dose chemotherapy for metastatic testicular cancer
por: Bokemeyer, C, et al.
Publicado: (2002)

Genomic Instability in Context of the Chromosomal Theory
por: Fabarius, Alice, et al.
Publicado: (2008)

Favored subjects and psychosocial needs in music therapy in terminally ill cancer patients: a content analysis
por: Preissler, Pia, et al.
Publicado: (2016)

Exploring the gender dimension of problems and needs of patients receiving specialist palliative care in a German palliative care unit - the perspectives of patients and healthcare professionals
por: Ullrich, Anneke, et al.
Publicado: (2019)

Capecitabine in the management of colorectal cancer
por: Hirsch, Bradford R, et al.
Publicado: (2011)

Capecitabine-Associated Loss of Fingerprints: Report of Capecitabine-Induced Adermatoglyphia in Two Women with Breast Cancer and Review of Acquired Dermatoglyphic Absence in Oncology Patients Treated with Capecitabine
por: Cohen, Philip R
Publicado: (2017)

Transconjunctival penetration of mitomycin C
por: Velpandian, T, et al.
Publicado: (2008)

Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction
por: Baird, R, et al.
Publicado: (2011)

Applications of Mitomycin C in Cornea and External Disease
por: Crespo, Marcos A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_03vnn4thd9tja7997psj8pcce8